These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28056030)

  • 1. Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.
    Asselah T; Moreno C; Sarrazin C; Gschwantler M; Foster GR; Craxí A; Buggisch P; Sanai F; Bicer C; Lenz O; Van Dooren G; Nalpas C; Lonjon-Domanec I; Schlag M; Buti M
    PLoS One; 2017; 12(1):e0168713. PubMed ID: 28056030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
    Wei L; Han T; Yang D; Heo J; Shang J; Cheng J; Chen X; Xie Q; Kim JH; Kalmeijer R; Ouwerkerk-Mahadevan S; Hoeben E; Lenz O; Verbinnen T; Sinha R; Li M; Scott J; Peeters M; Witek J;
    J Gastroenterol Hepatol; 2016 May; 31(5):912-20. PubMed ID: 26777137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).
    Asselah T; Moreno C; Sarrazin C; Gschwantler M; Foster GR; Craxí A; Buggisch P; Ryan R; Lenz O; Scott J; Van Dooren G; Lonjon-Domanec I; Schlag M; Buti M
    PLoS One; 2016; 11(7):e0158526. PubMed ID: 27428331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.
    Moreno C; Hezode C; Marcellin P; Bourgeois S; Francque S; Samuel D; Zoulim F; Grange JD; Shukla U; Lenz O; Ouwerkerk-Mahadevan S; Fevery B; Peeters M; Beumont M; Jessner W
    J Hepatol; 2015 May; 62(5):1047-55. PubMed ID: 25596313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
    Jacobson I; Zeuzem S; Flisiak R; Knysz B; Lueth S; Zarebska-Michaluk D; Janczewska E; Ferenci P; Diago M; Zignego AL; Safadi R; Baruch Y; Abdurakhmanov D; Shafran S; Thabut D; Bruck R; Gadano A; Thompson AJ; Kopit J; McPhee F; Michener T; Hughes EA; Yin PD; Noviello S
    World J Gastroenterol; 2016 Mar; 22(12):3418-31. PubMed ID: 27022224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
    Forns X; Lawitz E; Zeuzem S; Gane E; Bronowicki JP; Andreone P; Horban A; Brown A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Scott J; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Gastroenterology; 2014 Jun; 146(7):1669-79.e3. PubMed ID: 24602923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.
    Gane EJ; DeJesus E; Janczewska E; George J; Diago M; Da Silva MH; Reesink H; Nikitin I; Hinrichsen H; Bourgeois S; Ferenci P; Shukla U; Kalmeijer R; Lenz O; Fevery B; Corbett C; Beumont M; Jessner W
    BMC Infect Dis; 2017 Jun; 17(1):389. PubMed ID: 28577353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.
    D'Offizi G; Cammà C; Taibi C; Schlag M; Weber K; Palma M; DeMasi R; Janssen K; Witek J; Lionetti R
    New Microbiol; 2017 Jan; 40(1):19-26. PubMed ID: 28072888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
    Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
    Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.
    Izumi N; Hayashi N; Kumada H; Okanoue T; Tsubouchi H; Yatsuhashi H; Kato M; Ki R; Komada Y; Seto C; Goto S
    J Gastroenterol; 2014 May; 49(5):941-53. PubMed ID: 24626851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.
    Zeuzem S; Berg T; Gane E; Ferenci P; Foster GR; Fried MW; Hezode C; Hirschfield GM; Jacobson I; Nikitin I; Pockros PJ; Poordad F; Scott J; Lenz O; Peeters M; Sekar V; De Smedt G; Sinha R; Beumont-Mauviel M
    Gastroenterology; 2014 Feb; 146(2):430-41.e6. PubMed ID: 24184810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.
    Rodriguez-Torres M; Lawitz E; Yangco B; Jeffers L; Han SH; Thuluvath PJ; Rustgi V; Harrison S; Ghalib R; Vierling JM; Luketic V; Zamor PJ; Ravendhran N; Morgan TR; Pearlman B; O'Brien C; Khallafi H; Pyrsopoulos N; Kong G; McPhee F; Yin PD; Hughes E; Treitel M
    Ann Hepatol; 2016 Nov-Dec 2016; 15(6):834-845. PubMed ID: 27740516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.
    Hayashi N; Seto C; Kato M; Komada Y; Goto S
    J Gastroenterol; 2014 Jan; 49(1):138-47. PubMed ID: 24005956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
    Manns MP; Vierling JM; Bacon BR; Bruno S; Shibolet O; Baruch Y; Marcellin P; Caro L; Howe AY; Fandozzi C; Gress J; Gilbert CL; Shaw PM; Cooreman MP; Robertson MN; Hwang P; Dutko FJ; Wahl J; Mobashery N
    Gastroenterology; 2014 Aug; 147(2):366-76.e6. PubMed ID: 24727022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
    Kumada H; Mochida S; Suzuki F; Chayama K; Karino Y; Nakamura K; Fujimoto G; Howe AY; Ludmerer SW; Mobashery N
    J Gastroenterol Hepatol; 2016 Oct; 31(10):1674-1683. PubMed ID: 26936417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
    Sulkowski MS; Vargas HE; Di Bisceglie AM; Kuo A; Reddy KR; Lim JK; Morelli G; Darling JM; Feld JJ; Brown RS; Frazier LM; Stewart TG; Fried MW; Nelson DR; Jacobson IM;
    Gastroenterology; 2016 Feb; 150(2):419-29. PubMed ID: 26497081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.
    Hayashi N; Izumi N; Kumada H; Okanoue T; Tsubouchi H; Yatsuhashi H; Kato M; Ki R; Komada Y; Seto C; Goto S
    J Hepatol; 2014 Aug; 61(2):219-27. PubMed ID: 24727123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.